Published in J Neurochem on March 18, 2015
Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. Mol Psychiatry (2016) 0.89
Genetics ignite focus on microglial inflammation in Alzheimer's disease. Mol Neurodegener (2015) 0.85
The role of APOE in cerebrovascular dysfunction. Acta Neuropathol (2016) 0.84
microRNA-Based Biomarkers and the Diagnosis of Alzheimer's Disease. Front Neurol (2015) 0.83
Oxidized cholesterol as the driving force behind the development of Alzheimer's disease. Front Aging Neurosci (2015) 0.83
Neuronal Pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer's disease spectrum. Brain Behav Immun (2016) 0.82
Actin dynamics and cofilin-actin rods in alzheimer disease. Cytoskeleton (Hoboken) (2016) 0.80
APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. Oncotarget (2015) 0.79
Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes. Cell Mol Life Sci (2017) 0.79
Epidermal growth factor prevents oligomeric amyloid-β induced angiogenesis deficits in vitro. J Cereb Blood Flow Metab (2016) 0.78
Genetic Variations as Modifying Factors to Dietary Zinc Requirements-A Systematic Review. Nutrients (2017) 0.78
Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies. Int J Mol Sci (2016) 0.78
Epidermal growth factor prevents APOE4 and amyloid-beta-induced cognitive and cerebrovascular deficits in female mice. Acta Neuropathol Commun (2016) 0.77
Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. JAMA Psychiatry (2016) 0.76
Role of membrane biophysics in Alzheimer's-related cell pathways. Front Neurosci (2015) 0.76
Apolipoprotein E isotype-dependent modulation of microRNA-146a in plasma and brain. Neuroreport (2016) 0.75
Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease. Curr Opin Lipidol (2016) 0.75
Peripheral Inflammatory Markers and Antioxidant Response during the Post-Acute and Chronic Phase after Severe Traumatic Brain Injury. Front Neurol (2016) 0.75
Interactions between inflammation, sex steroids, and Alzheimer's disease risk factors. Front Neuroendocrinol (2016) 0.75
APOE ε4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive Impairment/Alzheimer's Disease. Aging (Albany NY) (2017) 0.75
Alternative activation of macrophages. Nat Rev Immunol (2003) 27.53
Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 26.08
The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 19.38
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med (2012) 10.16
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci (2006) 6.52
Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron (2006) 6.38
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A (1989) 5.97
Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A (2003) 5.11
Macrophage polarization in bacterial infections. J Immunol (2008) 4.67
In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem (2002) 4.20
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol (2013) 4.16
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci (2009) 3.97
Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat Neurosci (2013) 3.94
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J (2006) 3.92
Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci (2008) 3.90
Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem (1996) 3.84
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature (2012) 3.80
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA (2013) 3.78
Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol (2011) 3.56
The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci (2002) 3.55
Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol (2002) 3.53
Matrix metalloproteinases in neuroinflammation. Glia (2002) 3.51
Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov (2010) 3.35
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int (2002) 3.10
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem (1997) 3.04
Microglia: scapegoat, saboteur, or something else? Science (2013) 2.94
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol (2008) 2.86
Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol (1999) 2.85
Resolving controversies on the path to Alzheimer's therapeutics. Nat Med (2011) 2.78
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol (2012) 2.75
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
The microglial sensome revealed by direct RNA sequencing. Nat Neurosci (2013) 2.73
Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem (1982) 2.71
Role of toll-like receptor signalling in Abeta uptake and clearance. Brain (2006) 2.70
Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci (2014) 2.59
Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol (2009) 2.59
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology (2007) 2.54
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci (2013) 2.51
Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proc Natl Acad Sci U S A (2013) 2.45
Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis (2009) 2.44
TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol (2009) 2.44
Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res (1999) 2.39
Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med (2012) 2.36
The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol (1996) 2.34
Antiamyloid therapy for Alzheimer's disease--are we on the right road? N Engl J Med (2014) 2.29
Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res (2008) 2.28
Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis (2008) 2.27
Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation (2006) 2.23
Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia (2010) 2.23
ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem (2004) 2.19
Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis (2005) 2.16
Toll-like receptors in neurodegeneration. Brain Res Rev (2008) 2.15
Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis (2006) 2.14
Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem (2007) 2.12
Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis (2009) 2.12
Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci U S A (2007) 2.06
Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology (2002) 2.06
A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal (2012) 2.03
Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci (2006) 2.01
Cultured astrocytes express toll-like receptors for bacterial products. Glia (2003) 2.01
Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci (2011) 2.01
Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
Differential activation of astrocytes by innate and adaptive immune stimuli. Glia (2005) 1.99
Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci (2008) 1.92
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation (2014) 1.83
Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem (2004) 1.82
Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging (2001) 1.79
APOE genotype-specific differences in the innate immune response. Neurobiol Aging (2007) 1.75
The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev (1997) 1.73
Toll-like receptor 4 in CNS pathologies. J Neurochem (2010) 1.68
Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation (2008) 1.67
Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun (2013) 1.66
Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol (2012) 1.66
Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest (1991) 1.64
Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain (2013) 1.64
Apolipoprotein E: from lipid transport to neurobiology. Prog Lipid Res (2010) 1.63
Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest (1998) 1.61
Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res (2007) 1.59
Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int Rev Neurobiol (2007) 1.59
Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry (2011) 1.59
Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis (2003) 1.59
Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation (2008) 1.59
Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol (2004) 1.58
Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol (2008) 1.58
Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci (2010) 1.57
ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci U S A (2010) 1.57
The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ (2006) 1.55
Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem (2002) 5.63
In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem (2002) 4.20
Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest (2005) 3.15
Hydrocarbon-degrading bacteria and the bacterial community response in gulf of Mexico beach sands impacted by the deepwater horizon oil spill. Appl Environ Microbiol (2011) 2.47
Massively parallel rRNA gene sequencing exacerbates the potential for biased community diversity comparisons due to variable library sizes. Environ Microbiol (2011) 2.28
Hippocampal sclerosis in advanced age: clinical and pathological features. Brain (2011) 2.16
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation (2007) 1.70
Protein kinase involved in lung injury susceptibility: evidence from enzyme isoform genetic knockout and in vivo inhibitor treatment. Proc Natl Acad Sci U S A (2003) 1.62
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
Epigenetic repression of the Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2. Nat Immunol (2011) 1.59
Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J Neuroinflammation (2008) 1.57
Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected]. Brain Res (2009) 1.53
Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity (2013) 1.52
University of Kentucky Sanders-Brown healthy brain aging volunteers: donor characteristics, procedures and neuropathology. Curr Alzheimer Res (2012) 1.52
Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J Alzheimers Dis (2002) 1.48
Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov (2009) 1.45
Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging (2004) 1.42
Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol (2013) 1.41
Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci (2006) 1.39
Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis (2005) 1.39
The discriminatory cost of ICD-10-CM transition between clinical specialties: metrics, case study, and mitigating tools. J Am Med Inform Assoc (2013) 1.35
Glial activation links early-life seizures and long-term neurologic dysfunction: evidence using a small molecule inhibitor of proinflammatory cytokine upregulation. Epilepsia (2007) 1.32
Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol Aging (2010) 1.32
ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. Neurobiol Dis (2005) 1.30
Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci (2012) 1.27
Preparing synthetic Aβ in different aggregation states. Methods Mol Biol (2011) 1.26
Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ). J Neuroinflammation (2011) 1.25
CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease. Clin Gastroenterol Hepatol (2004) 1.25
ApoE isoform affects LTP in human targeted replacement mice. Neuroreport (2004) 1.24
A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity. J Mol Neurosci (2004) 1.24
Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia (2006) 1.22
Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem (2010) 1.20
MFG-E8 regulates microglial phagocytosis of apoptotic neurons. J Neuroimmune Pharmacol (2008) 1.20
Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38. Glia (2004) 1.19
Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo. Neurobiol Aging (2004) 1.18
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett (2006) 1.18
A self-reinforcing regulatory network triggered by limiting IL-7 activates pre-BCR signaling and differentiation. Nat Immunol (2012) 1.18
Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking. PLoS One (2010) 1.17
Neuroinflammation: a potential therapeutic target. Expert Opin Ther Targets (2005) 1.16
Genome sequences for six Rhodanobacter strains, isolated from soils and the terrestrial subsurface, with variable denitrification capabilities. J Bacteriol (2012) 1.16
Differential regulation of amyloid-β endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J Biol Chem (2012) 1.15
Molecular and morphological characterization of cyanobacterial diversity in the stromatolites of Highborne Cay, Bahamas. ISME J (2009) 1.14
A limited microbial consortium is responsible for extended bioreduction of uranium in a contaminated aquifer. Appl Environ Microbiol (2011) 1.14
Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain (2013) 1.13
S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors. J Neurochem (2005) 1.13
ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. J Mol Neurosci (2004) 1.10
The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS. Aging Dis (2010) 1.09
Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Neurobiol Aging (2006) 1.09
Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody. Mol Neurodegener (2012) 1.09
The p38α MAPK regulates microglial responsiveness to diffuse traumatic brain injury. J Neurosci (2013) 1.08
Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem (2013) 1.07
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol (2014) 1.07
MCP-1-deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult. J Neuroinflammation (2008) 1.07
Effects of nitrate on the stability of uranium in a bioreduced region of the subsurface. Environ Sci Technol (2010) 1.06
Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol (2010) 1.06
APOE genotype alters glial activation and loss of synaptic markers in mice. Glia (2012) 1.04
Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition. J Alzheimers Dis (2011) 1.03
Microglial p38α MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFα. Mol Neurodegener (2011) 1.03
Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation. J Mol Neurosci (2004) 1.02
Enhanced microglial activation and proinflammatory cytokine upregulation are linked to increased susceptibility to seizures and neurologic injury in a 'two-hit' seizure model. Brain Res (2009) 1.01
Mild cognitive impairment: statistical models of transition using longitudinal clinical data. Int J Alzheimers Dis (2012) 1.01
Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid. J Neuroinflammation (2005) 1.01
Cellular catabolism of lipid poor apolipoprotein E via cell surface LDL receptor-related protein. J Biochem (2002) 1.01
Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. J Neurosci Methods (2011) 1.00
Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging (2011) 0.99
Genome sequences for three denitrifying bacterial strains isolated from a uranium- and nitrate-contaminated subsurface environment. Genome Announc (2013) 0.99
Psoriasin (S100A7) and calgranulin-B (S100A9) induction is dependent on reactive oxygen species and is downregulated by Bcl-2 and antioxidants. Cancer Biol Ther (2005) 0.98
Smoking cessation behavior in older adults by race and gender: the role of health problems and psychological distress. Nicotine Tob Res (2009) 0.98
Adjusting for mortality when identifying risk factors for transitions to mild cognitive impairment and dementia. J Alzheimers Dis (2013) 0.97
Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. PLoS One (2013) 0.96
Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model. Curr Alzheimer Res (2005) 0.95
Draft genome sequences for oil-degrading bacterial strains from beach sands impacted by the deepwater horizon oil spill. Genome Announc (2013) 0.95
Draft Genome Sequence of Alicyclobacillus acidoterrestris Strain ATCC 49025. Genome Announc (2013) 0.94
Restriction site-associated DNA sequencing generates high-quality single nucleotide polymorphisms for assessing hybridization between bighead and silver carp in the United States and China. Mol Ecol Resour (2013) 0.93
Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin. Mol Neurodegener (2014) 0.93
Religious attendance reduces cognitive decline among older women with high levels of depressive symptoms. J Gerontol A Biol Sci Med Sci (2009) 0.92
Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound. J Med Chem (2002) 0.92
Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. J Neurochem (2004) 0.92
Myosin light chain kinase (210 kDa) is a potential cytoskeleton integrator through its unique N-terminal domain. Exp Cell Res (2004) 0.92
Increased susceptibility of S100B transgenic mice to perinatal hypoxia-ischemia. Ann Neurol (2004) 0.92
Cognitive impairment in humanized APP×PS1 mice is linked to Aβ(1-42) and NOX activation. Neurobiol Dis (2011) 0.91
Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol (2014) 0.91
Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition. J Neuroinflammation (2014) 0.90
"End-stage" neurofibrillary tangle pathology in preclinical Alzheimer's disease: fact or fiction? J Alzheimers Dis (2011) 0.90
The generation and function of soluble apoE receptors in the CNS. Mol Neurodegener (2006) 0.89
Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease. Alzheimers Dement (2013) 0.89
Development and validation of a yeast high-throughput screen for inhibitors of Aβ₄₂ oligomerization. Dis Model Mech (2011) 0.88
Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug. J Neuroimmunol (2008) 0.88
De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders. Curr Alzheimer Res (2006) 0.88
Competing factors of compost concentration and proximity to root affect the distribution of streptomycetes. Microb Ecol (2005) 0.88
Draft Genome Sequence of Rhodococcus opacus Strain M213 Shows a Diverse Catabolic Potential. Genome Announc (2013) 0.88
Geobacter daltonii sp. nov., an Fe(III)- and uranium(VI)-reducing bacterium isolated from a shallow subsurface exposed to mixed heavy metal and hydrocarbon contamination. Int J Syst Evol Microbiol (2009) 0.87
Inhibition of neuronal p38α, but not p38β MAPK, provides neuroprotection against three different neurotoxic insults. J Mol Neurosci (2014) 0.86
Self-reported head injury and risk of late-life impairment and AD pathology in an AD center cohort. Dement Geriatr Cogn Disord (2013) 0.86
Simultaneous analysis of dendritic spine density, morphology and excitatory glutamate receptors during neuron maturation in vitro by quantitative immunocytochemistry. J Neurosci Methods (2012) 0.85
APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. Mol Neurodegener (2015) 0.85